Holen Sie sich die Stockscreener-App
2.88
5.57%
-0.17
Handel nachbörslich:
2.88
Lixte Biotechnology Holdings Inc Aktie (LIXT) Neueste Nachrichten
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXT Technical Analysis & Stock Price Forecast - Intellectia AI
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - NewMediaWire
LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes - TipRanks
LIXTE Biotechnology Reports Transformational Year with Clinical Progress and Strategic Expansion - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - TipRanks
Lixte Biotech Receives Going Concern Alert Amid Insider and Institutional Sell-Offs—Who Will Fund the Recovery? - Bitget
LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials - newmediawire.com
LIXTE Biotechnology's LB-100 Emerges as Sole Clinical-Stage PP2A Inhibitor in Cancer Treatment Development - citybuzz -
Cancer drug study doubles to 42 patients after LIXTE's $11M raise - Stock Titan
LIXTE Biotechnology’s Expanded Trial Could Be Its Best Shot at Breaking the Stagnation - Bitget
Lixte Biotechnology | 10-K: FY2025 Annual Report - Moomoo
Lixte Biotechnology Holdings 10-K: $0 Revenue, $(1.26) EPS - TradingView
Lixte Biotechnology (NASDAQ: LIXT) posts larger loss and flags going-concern risk - Stock Titan
LIXTE Biotechnology Expands Clinical Trials for LB-100 in Challenging Ovarian and Colon Cancers - citybuzz -
Quarterly Earnings: Is Lixte Biotechnology Holdings Inc attractive for institutional investorsWeekly Trade Report & Daily Profit Focused Screening - baoquankhu1.vn
Lixte Biotechnology Stock: Precision Oncology Pioneer with High-Risk Development Pipeline for North - AD HOC NEWS
Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership - Benzinga
De La Soul Set to Lead Good Health Summit at Morehouse College - EBONY Magazine
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (NASDAQ: LIXT) Saw It Coming - The Globe and Mail
Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming - NewMediaWire
Treasury Yields: Can Lixte Biotechnology Holdings Inc Equity Warrant sustain its profitabilityEarnings Growth Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Pharma News: Whats the profit margin of Lixte Biotechnology Holdings IncStock Surge & Safe Capital Growth Trade Ideas - baoquankhu1.vn
LIXTE Biotechnology (NASDAQ: LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - The Globe and Mail
LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape - NewMediaWire
Market Fear: Can Lixte Biotechnology Holdings Inc. Equity Warrant be recession proofFed Meeting & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Lixte Biotechnology Raises CEO Compensation Amid Leadership Support - TipRanks
Lixte (NASDAQ: LIXT) lifts CEO Geordan Pursglove base salary to $360k - Stock Titan
Lixte Biotechnology boosts CEO Geordan Pursglove's base salary to $360,000 - TradingView
Lixte Biotechnology stock faces scrutiny amid stalled pipeline progress and biotech sector volatilit - AD HOC NEWS
LIXTE Biotechnology Advances PP2A Inhibition Strategy to Enhance Cancer Treatment Combinations - citybuzz -
Lixte Biotechnology shares slide following purchase of UK-based Liora - MSN
Guidance Update: Is Lixte Biotechnology Holdings Inc a stock for growth or value investorsWeekly Gains Summary & Real-Time Chart Breakout Alerts - baoquankhu1.vn
Breakout Move: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proofWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Faces Short-Term Pressure Amid Strong Rising Trend an - AD HOC NEWS
Bond Watch: Does Lixte Biotechnology Holdings Inc align with a passive investing strategyOil Prices & Daily Stock Trend Watchlist - baoquankhu1.vn
LIXTE Biotechnology and Liora Technologies Partner to Advance Combined Cancer Treatment Approach - citybuzz -
Aug PostEarnings: Can Lixte Biotechnology Holdings Inc Equity Warrant be recession proof2026 Intraday Action & Stock Portfolio Risk Control - baoquankhu1.vn
Lixte Biotechnology Stock (ISIN: US53833K1060) Trades Steadily Amid Clinical-Stage Oncology Focus - AD HOC NEWS
Is Lixte Biotechnology Holdings Inc stock technically oversold2026 Rallies & AI Forecasted Entry/Exit Points - baoquankhu1.vn
LIXTE Biotechnology Expands Ovarian Cancer Trial Through MD Anderson and GSK Partnership - citybuzz -
Lixte Amends Share Exchange, Clarifies Liora Ownership Structure - The Globe and Mail
Lixte Biotechnology Enters Amended Share Exchange to Consolidate Liora Ownership With Orbit Capital - TradingView
Lixte (NASDAQ: LIXT) restates Liora share exchange and Orbit’s 20% stake - Stock Titan
LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline - Yahoo Finance
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline - TipRanks
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):